Patents Examined by Heidi Reese
  • Patent number: 11453674
    Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Assignee: EVOPOINT BIOSCIENCES CO., LTD.
    Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu, Linhai Qu, Jinlian Zhu, Xiao Liu
  • Patent number: 11447484
    Abstract: Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like; r is an integer of 0 to 4; -L- is —N(R10)—C(?O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 20, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yusuke Ichihashi, Masanao Inagaki, Koji Masuda
  • Patent number: 11446287
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 20, 2022
    Assignee: Opna Immuno-Oncology SA
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • Patent number: 11440898
    Abstract: The application is directed to compounds of formula (I):(I), and formula (IA):(IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: September 13, 2022
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Marc Martinell Pedemonte, Elena Cubero Jordà, Xavier Barril Alonso, Laura Pilar Rodriguez Pascau
  • Patent number: 11439635
    Abstract: Disclosed are methods and compositions for treating diabetes mellitus and non-alcoholic fatty liver disease by administering a therapeutic agent that inhibits the biological activity of B cell lymphoma 6 protein (BCL6).
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: September 13, 2022
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Grant D. Barish, Meredith A. Sommars, Madhavi D. Senagolage
  • Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 11433061
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 6, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
  • Patent number: 11433048
    Abstract: The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 6, 2022
    Inventors: Nicolas Pietrancosta, Nikaïa Smith, Jean-Philippe Herbeuval
  • Patent number: 11426394
    Abstract: A method is provided to prevent and to treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where Macular Degeneration is formed, to increase the capillary network and blood supply to the retinal macula.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: August 30, 2022
    Inventor: Assa Weinberg
  • Patent number: 11427558
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Patent number: 11427578
    Abstract: The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 30, 2022
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Jeffrey Stuart Mowat, Bernd Buchmann, Nuria Aiguabella Font, Gabriele Leder, Rafael Carretero, Olaf Panknin, Roland Neuhaus, Robin Michael Meier, Sandra Berndt, Kirstin Petersen, Rienk Offringa
  • Patent number: 11419875
    Abstract: The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: August 23, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Kavitha Nellore, Girish Daginakatte, Wesley R. Balasubramanian
  • Patent number: 11420956
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: August 23, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11422091
    Abstract: This invention is in the field of fluorescence imaging and relates to a new near infrared (NIR) reactive oxygen species (ROS) sensor designed with controlled fluorescence on-off switching mechanism.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: August 23, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventor: Maolin Guo
  • Patent number: 11420963
    Abstract: Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: August 23, 2022
    Assignees: SAMJIN PHARMACEUTICAL CO., LTD., ASTECH. CO., LTD.
    Inventors: Eui Hwan Cho, Sung Ju Choi, Sung Woo Lee, Hee Jong Shin, Ho Seok Kwon, Jae Woong Lee, Jeong Ho Joo, Hyun Tae Kim, Woo Heon Song, Jong Bae Yoon, Ki Seok Park, Ho Joon Park, Ho Tae Nam
  • Patent number: 11414399
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 16, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • Patent number: 11406612
    Abstract: Resolution of a pathological condition is promoted via the application, e.g., via injection, of a potassium osmolyte such as hyperosmolar potassium gluconate, potassium aspartate, another potassium-based salt, or combinations thereof to the condition site. The application of the potassium osmolyte increases the extracellular concentration of potassium ions, reducing the membrane potential of the cells at the condition site and including immune cell quiescence. As a result, the inflammatory response in the patient to the pathological condition is reduced or eliminated. Reducing the inflammatory response is useful in treatment of myriad conditions including arthritis, auto-immune conditions, inflammatory disorders, neurodegenerative disorders, neurodevelopmental disorders, tissue breakdown, etc.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 9, 2022
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Joshua Erndt-Marino, Mariah Hahn
  • Patent number: 11407734
    Abstract: Provided is a preparation method for a tyrosine kinase inhibitor and an intermediate thereof. Specifically, a preparation method for a cyanoquinoline compound is provided. The method has a high yield, good product purity, and mild reaction conditions.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: August 9, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guobing Feng, Yongxing Cao, Peng Zhang, Zhenjun Qiu, Long Zhang
  • Patent number: 11407732
    Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: August 9, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
  • Patent number: 11401256
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: August 2, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert